Patent SG-11201903420S-A (SG)
Title: Antisense oligonucleotides
Inventor: SURANA UTTAM
IPC: A61P35/00
Filed: 2017-10-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 0111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/080393 Al 03 May 2018 (03.05.2018) W I P0 I P C T (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C12N 15/113 (2010.01) A61P 35/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/7088 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/SG2017/050517 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 16 October 2017 (16.10.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201609048R 28 October 2016 (28.10.2016) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). (72) Inventors: SURANA, Uttam; c/o Agency for Science, Technology and Research, 1, Connexis, Fusionopolis Way, #20-10, Singapore 138632 (SG). WEE, Keng Boon; c/o Agency for Science, Technology and Research, 1, Con- nexis, Fusionopolis Way, #20-10, Singapore 138632 (SG). LIN, Jing; c/o Agency for Science, Technology and Re- search, 1, Connexis, Fusionopolis Way, #20-10, Singapore 138632 (SG). LIM, Bing; c/o Agency for Science, Technol- ogy and Research, 1 Connexis, Fusionopolis Way, #20-10, Singapore 138632 (SG). Agent: AMICA LAW LLC; 30 Raffles Place, #14-01 (74) Chevron House, Singapore 048622 (SG). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (84) - .4 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, M 01 0 en (54) Title: ANTISENSE OLIGONUCLEOTIDES *t (57) : The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). 0 ---- In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are GO pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In Il © addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient N with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided. C